NIH Establishes Monkey Model for MERS-CoV

An NIH study suggests that marmoset models are the optimum option for testing new drugs for MERS Scientists from the National Institutes of Health have found that the Middle East Respiratory (MERS) virus in marmosets provokes a very similar response to humans afflicted with MERS caused pneumonia. The doctors began testing MERS treatments on marmosets after using computer models to …

Pfizer's Pneumococcal Vaccine Could See a Boost in Sales After the CDC's Recommendation for Use in Older Adults

Pfizer’s Prevnar 13 Could See a $2 Billion Boost in Sales

Pfizer’s Pneumococcal Vaccine Could See a Boost in Sales After the CDC’s Recommendation for Use in Older Adults On Wednesday, Pfizer announced that the CDC’s Advisory Committee on Immunisation Practices (ACIP) has decided to recommend and promote the Prevnar 13 pneumococcal vaccine for use in adults aged 65 and up. The vaccine protects against pneumococcal diseases including pneumonia, which can …

Interactive Map: Advance market commitment for pneumococcal vaccines

This map shows the availability of pneumococcal vaccines PCV10 and PCV13 through the Advanced Market Commitment scheme designed to get life saving vaccines to the developing world as fast and reliably as possible. *Source: Advance Market Commitment for Pnewumococcal Vaccines, Annual Report 1 April 2013 – 31 March 2014, prepared by the GAVI Alliance Click here to see our Advance …

Pfizer Reaches Primary and Secondary Objectives in Landmark Community-Acquired Pneumonia Vaccination Trial

February 24, 2014 Pfizer Inc. today announced that the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects evaluating the efficacy of Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 65 years of age and older, achieved its primary clinical objective and both secondary clinical objectives.  CAPiTA is the largest double-blind, randomized, placebo-controlled …